In the recent review by Ye published in this journal, the emerging role of adipose tissue hypoxia is discussed with respect to obesity and insulin resistance. 1 This is a timely review as it would appear that tissue hypoxia may not just be confined to adipose tissue but may well be a problem, or rather perhaps the cause, of a number of diseases that might have a common aetiology, such as obesity, diabetes and perhaps even cancer and hypertension. It has been observed that obese patients have tissue hypoxia thus making it more difficult to operate with an increased risk of wound infection. 2 Others have observed that increased perioperative fluid administration increases significantly tissue perfusion and oxygen partial pressure in normal weight patients 3 and thus aids healing. This would suggest that there could be a link between hypovolaemia and tissue hypoxia and that in obese patients this hypovolaemia is more aggravated. Hypovolaemia-induced angiotensin release has been implicated in obesity through its capacity to decrease membrane glucose transport and insulin sensitivity as giving antagonists of the AT1 angiotensin-specific receptor decreases insulin resistance. 4 Decreased glucose availability would imply dysfunction of cell metabolism through disruption of mitochondrial activity, which may be a common denominator of obesity and other elements of the metabolic syndrome, such as diabetes and hypertension. Furthermore, in the kidney, chronic hypoxia leads to activation of the renin-angiotensin system, 5 thus confirming a link between hypovolaemia and tissue hypoxia. This angiotensin has been implicated also in the regulation of erythropoietin production as part of the effecter signals of the feedback loop of blood volume regulation. 6 This would imply that with hypovolaemia there is a situation of chronic (perhaps mild) hypoxia. Added to this is the finding that chronic hypoxia activates the hypoxia-inducible factor 1 system, which activates several enzymatic pathways to decrease mitochondrial use of oxygen and to initiate glycolytic pathways. 7 This would have the effect also of decreasing mitochondrial function, independent of substrate availability, and thus decreasing also cell metabolism, exactly as described for the obese condition.
Thus it would appear that it might be hypovolaemia that induces subchronic metabolic dysfunction through hypoxiainduced mitochondrial dysfunction through lowered tissue perfusion and thus lowered oxygen supply. It would thus be of interest to study the behaviour and function of red blood cells and their capacity to transport oxygen under conditions of chronic hypovolaemia. 
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